Table 1 Other laboratory findings
From: Systemic inflammation and chronic kidney disease in a patient due to the RNASEH2B defect
Parameters | Before tocilizumab | 12 weeks after tocilizumab | Before tofacitinib | 48 weeks after tofacitinib | Reference Range |
|---|---|---|---|---|---|
Rheumatoid factor (IU/ml) | 879 | 810 | 2615 | 2660 | 0–20 |
Protein in CSF (mg/L) | 541.9 | NA | NA | NA | 150–450 |
WBCs in CSF (106/L) | 1 | NA | NA | NA | 0–15 |
interferon-α in CSF (pg/ml) | 22.1 | NA | NA | NA | NA |
interferon-α in plasma (pg/ml) | 1627 | 1040 | 2309 | 1601.4 | 139.64 ± 96.54 |
IP10 in plasma (pg/ml) | 2172 | 2160 | 3702 | 2135 | 397.43 ± 159.51 |
IFNγ in plasma (pg/ml) | 453.6 | 260.8 | 850.5 | 282.9 | 26.32 ± 11.24 |
TNFa in plasma (pg/ml) | 335.4 | 232.9 | 554.6 | 259.1 | 42.05 ± 14.76 |
IL1β in plasma (pg/ml) | 224.15 | 208 | 274.3 | 218 | 7.75 ± 6.5 |
IL4 in plasma (pg/ml) | 311 | 135.6 | 473 | 252 | 29.81 ± 18.48 |
IL6 in plasma (pg/ml) | 221 | 142.6 | 230.3 | 156.2 | 5.5 ± 3.39 |
IL10 in plasma (pg/ml) | 1025 | 540.9 | 731.4 | 568.6 | 14.36 ± 9.88 |
IL12 in plasma (pg/ml) | 1507 | 1389 | 1372 | 1337 | 149.32 ± 139.9 |
IL17A in plasma (pg/ml) | 64.9 | 44.8 | 43.7 | 48 | 15.55 ± 10.13 |
GM-CSF in plasma (pg/ml) | 1146 | 1053 | 1067 | 1073.6 | 68.36 ± 44.74 |